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The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee
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W
ith the introduction of the Social Security
Funding Law for the year 2008, the French
National Authority for Health (Haute Autorite´
de Sante´, or HAS) has been commissioned to produce
‘health economic opinions’, determine the most cost-effective
therapeutic strategies, and edit the recommendations
accordingly (1). An affiliate organ named the Economic
and Public Health Assessment Committee (Commission
Evaluation Economique et de Sante´ Publique, or CEESP)
has been set up to fulfil this mission. The Social Security
Funding Law for 2012 (2) introduced the CEESP in the
Social Security Code as a specialised committee in charge
of providing recommendations and health economic
opinions. This decision came as part of an effort not only
to confront the increasing deficit of the Social Security
System and encourage it to recover a healthy financial
balance but also in response to the French Court of
Auditors (Cours des Comptes), which regularly challenged
the lack of economic evidence use in pricing decisions (3).
The law and the application decree still leave areas of
uncertainty, making it difficult to appreciate the place and
role of health economics. There are evident conflicting rules
following the introduction of the health economic assess-
ment in France that request clarification and resolution. The
current situation should be considered to be a transitional
period, and major steps are expected in the near future.
This article aims to provide an in-depth description
of the CEESP’s structure and working methods, as well
as to analyse the impact of health economic assessment
on market access of drugs in France. It may help readers
appreciate the current management of conflicting situa-
tions and put it in context in the overall health technology
assessment (HTA) in France. It also provides likely direc-
tions of future French HTA organisation and processes.
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Description of the CEESP
Context of the CEESP implementation and legislation
It was the Social Security Funding Law for 2008 that first
assigned the HAS the task of producing recommenda-
tions and health economic opinions on the most cost-
effective medical care and prescription strategies (Article
L161-37) (1).
The CEESP was created for this purpose in 2008,
4 years after the creation of the HAS. However, up until
2012, this committee operated as an internal group within
HAS and exclusively provided health strategic advice.
Until then, it was not mentioned in the Social Security
Code and did not exist as an independent legal entity
within HAS. Therefore, the opinions and recommen-
dations issued by the CEESP had a relatively low impact
on the pricing and reimbursement of health products.
Moreover, the CEESP used to review old products with
limited question marks on pricing (4).
In an effort to enhance the financial sustainability of
the healthcare system, the Social Security Funding Law
for 2012 introduced the CEESP as a specialised commit-
tee under Article 47 of the Social Security Code, in charge
of providing recommendations and health economic
opinions. Concurrently, the board and structure of this
committee were remodelled to suit these new prerogatives
(Fig. 1) (2).
Aim of the CEESP
The establishment of the CEESP is part of an effort to
ascertain that both public and professionals’ decisions
in the medical field (particularly in terms of pricing
and reimbursement) take into consideration the notions
of cost-effectiveness and opportunity cost.
Within the framework of its core mission, the CEESP
is expected to guarantee the scientific validity, the meth-
odology, and the ethics of the work that HAS conducts
in economic and public health evaluation (5). Topics
with a high potential for expense optimisation are priori-
tised, particularly during the reassessment of therapeutic
classes or the assessment of medical care strategies from
a medium-term perspective (5).
Missions
According to the CEESP rules of procedure (6) and
within the framework of the missions entrusted to it, the
committee is expected to deliver health economic opi-
nions on medical procedures, products, or health services
(Article L.161-37, 1st paragraph of the Social Security
Code); to perform or validate the health economic studies
necessary for the evaluation of health products and tech-
nologies (Article L.161-37, 1st paragraph of the Social
Security Code); and to set up or spread health economic
recommendations on the most cost-effective care, pre-
scription, or coverage strategies.
The CEESP relies on the works of two services:
the Service of Economic Evaluation and Public Health
(Service e´valuation e´conomique et de sante´ publique, or
SEESP) and the Service of Evaluation of the Professional
Medical Procedures (Service Evaluation des Actes Pro-
fessionnels, or SEAP) (5) (Fig. 2). It is also required
to coordinate its health economic appraisal with the
medical appraisal performed by the Transparency Com-
mittee (Commission de la Transparence, or CT) and
the Medical Devices and Health Technologies Committee
(Commission Nationale d’Evaluation des Dispositifs
Me´dicaux et des Technologies de Sante´, or CNEDIMTS)
(5) (Fig. 3). The Device Evaluation Service (Service
Evaluation des Dispositifs Me´dicaux, or SED) and the
Medicines Evaluation Service (Service Evaluation des
Me´dicaments, or SEM) are in charge of examining the
dossiers for the CNEDIMTS and the CT, respectively.
All of the committees form part of the HAS and deliver
their opinions to the Economic Committee on Healthcare
Products (Comite´ Economique des Produits de Sante´,
or CEPS), which is under the joint authority of the min-
isters in charge of Health, Social Security, and Economy.
The CEPS is in charge of setting the prices of medicinal
products for individual use, which are covered by the
national health insurance (7) (Fig. 2).
Fig. 1. Establishment of the CEESP.
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Upon the request of the HAS College, the CEESP
can also be instructed to deliver its deliberations
concerning:
. The opinions referred to in Article L.161-40 of
the Social Security Code on the list of periodic
preventive medical consultations and the screenings
conducted as part of the health programs referred
to in Article L.161-37 of the Social Security Code
. Assessments of the public healthcare quality in
accordance to Article L.161-40, 3rd paragraph of
the Social Security Code
. The opinions related to the medical procedures
with aesthetic aims (Article L. 1151-3 of the Social
Security Code)
. The works that can be useful for the accomplish-
ment of HAS’ missions within the competence field
of the CEESP (6).
Composition
The CEESP is composed of 33 members with voting
rights, appointed by the College of the HAS for a period
of 3 years, which is renewable twice. The members in-
clude the president (appointed from the College mem-
bers), health professionals, personalities appointed for
their expertise in economic evaluation and public health
fields, and representatives of users’ or patients’ asso-
ciations. Two vice presidents are elected by the College
among these members.
Fig. 2. Organisation of the French HTA and pricing system. Dashed arrows indicate the support of the subcommittees/services to the
different committees in their work.
Fig. 3. The coordinated assessment/appraisal (8).
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In addition to the permanent members, other persons
who can play an advisory role can attend the committee
meetings like the representatives of ministers in charge
of Health and Social Security, representatives of health
insurance organisations, as well as other individuals from
within or outside the HAS. Any member of the College as
well as the director can attend the committee meetings.
The CEESP committee is composed of one-third
economists, one-third health professionals (including
public health doctors, epidemiologists, and field doc-
tors), as well as one-third representatives of social and
human sciences. This composition reflects the objective
of the CEESP: to combine the economic evaluation and
public health aspects (6).
Functioning
The secretariat is provided by the SEESP. It offers the
administrative help necessary for the functioning of the
CEESP and coordinates the works of the latter with
the activities of the other HAS committees.
In order to prepare its work, the CEESP meets in
subcommittees. More specifically, an economics subcom-
mittee and human and social science subcommittee can
be convened to proceed to prior methodological analyses
(Fig. 2). The subcommittees are chaired by a member
of the committee, and the minutes of the meeting are then
transmitted to the committee.
The bureau of the CEESP is composed of the
president, the two vice presidents, the two presidents
of the subcommittees, as well as the department head of
the SEESP. The missions of the bureau are to prepare the
meetings of the committee, to set the agenda, to appoint
the rapporteurs among the members of the committee,
to examine the potential conflicts of interest of the exter-
nal experts (and validate their participation), as well
as to rule on the written observations presented by the
companies during the adversarial phase, when these
observations are related to the form and not the content
of the opinions.
The periodicity of the CEESP meetings depends on
the number of files the committee has to examine. The
agenda and the documents related to the agenda items as
well as a draft of the record of the previous meeting
are filed to each member of the committee at least 5 days
before the committee meeting.
The rapporteurs are in charge of inspecting the rele-
vance and feasibility of the proposed works as well as
their methodological quality in accordance with the pre-
defined methods. They deliver their written report before
the meeting.
The president of the committee determines the sche-
dule, and convenes and chairs the meetings. If he or she
is absent or unable to act, the presidency of the meeting
is entrusted to a vice president or to another member of
the committee.
The committee can only deliberate if a majority of
its members are present. If this quorum is not met,
the committee must postpone the session. At the second
meeting, however, they must deliberate, no matter how
many members are present. The results of the voting are
established by a simple majority of the present members.
The meetings of the committee are recorded, in accor-
dance with Article L.1451-1-1 of the Social Security Code.
The recordings are retained by the services of the HAS
and can be published on the website of the HAS, upon
the request of the president of the HAS.
The minutes of the meetings are made public and
contain the agenda and the report of the meeting. The
latter includes the date of the meeting, the list of the
members present and those excused, the topics examined,
the participation and non-participation of the members
of the committee in view of the possible links of interest,
the content of the debates, the results of the voting,
and their possible explanation. The minutes are sub-
mitted for approval to the committee during the follow-
ing session. They are then circulated to the members
of the committee, all the participants of the meeting,
the director of the HAS, the members of the College,
and all of the representatives of the ministers in charge
of Health and Social Security. They are retained and
archived by the secretariat of the committee and pub-
lished on the HAS website.
Every year, the committee elaborates an activity report
that is presented to the Parliament according to Article L.
161-37 of the Social Security Code. This report includes
information related to the health economic opinions
rendered during the year in question and the guidelines
of the committee defined during the examination of the
files (6).
Health economic evaluation
Scope: for which products?
Decree No. 2012-1116 of 2 October 2012, related to the
health economic missions of the HAS, specifies the cases
for which a health economic assessment will be required
for drugs and medical devices (9).
In accordance with this decree, two criteria must be
met in order to proceed to the health economic assess-
ment of a health product:
1) The Improvement of the Medical Benefit (Ame´-
lioration du Service Me´dical Rendu, or ASMR) or
the improvement of the benefit (Ame´lioration du
Service Attendu, or ASA) claimed by the company
is major, important, or moderate (ASMR or ASA I,
II, or III); and
2) The health product is susceptible to having a signi-
ficant impact on the health insurance budget, or with
regard to its impact on healthcare organisations,
Mondher Toumi et al.
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professional practices, or patient care and, when
applicable, its price.
In 18 September 2013, the HAS complemented the
above definition of the range of products subject to
health economic assessment by setting a threshold of
t20 million yearly revenue to define the significant im-
pact on the health insurance budget. Therefore, a health
economic evaluation is now also required for first listing
and relisting of drugs and medical devices with yearly
projected revenues of t20 million or above.
The HAS College considers that economic valuation is
not required:
1) If a conventional price drop procedure is initiated;
or
2) If the product patent has expired (10).
General rules and guiding principles
In accordance with Decree No. 2012-1116 of 2 October
2012, health economic evaluation is conducted by the
CEESP, concomitantly and independently of the CT
assessment, and following a guideline related to metho-
dological choices for economic assessment issued by the
HAS in 2011 (11).
The guideline is very flexible even if some specific
recommendations were made (e.g., no costbenefit ana-
lysis, loss of productivity not included in reference case,
and deterministic and probabilistic sensitivity analysis
required). With regard to the methodology of evalua-
tion, the committee remains open to all options, as long
as they are well argued and scientifically sound (11).
The burden of proof lies with the manufacturer,
who must produce the evidence that supports its claim
in terms of ASMR/ASA, projected revenues and impact
on healthcare organisations, professional practices, and
patient care. Data are submitted by the manufacturer
to both the CEESP and the CEPS, along with the request
for inclusion/renewal of inclusion of the product on the
reimbursable drugs formulary. The submitted evidence is
scrutinised by the HAS board to determine the product’s
eligibility for health economic evaluation (5, 6).
File composition
The pharmaceutical company, along with the request
for inclusion/renewal of inclusion of a medicine on the
reimbursable drugs formulary, must transmit all health
economic data related to the drug to the CEESP and to
the CEPS, if the product falls under any of the cate-
gories concerned with health economic assessment. This
was detailed in the ‘Scope’ section of this article (12).
The composition of the file must be as follows:
1) A depositing slip available for download from the
HAS website and labelled ‘Depositing slip for a file
to be examined by the Economic and Public Health
Assessment Committee’. This form must be filled
out by applicants and will be returned to them as
an acknowledgement of receipt of their file.
2) A presentation report written in French contain-
ing all the necessary data for the health economic
evaluation. A template of the presentation report is
available for download from the HAS website (13).
It must contain the following information:
a. General information about the application.
b. Summary presentation of the cost-effectiveness
evaluation.
c. Objectives and results of the submitted study.
d. Methodological choices providing the struc-
ture for the cost-effectiveness evaluation.
e. Checklist labelled ‘Methods of evaluation
of budget impact’ (budget impact is not
mandatory).
f. Checklist labelled ‘Methods of evaluation of
cost-effectiveness’.
g. Inventory of existing cost-effectiveness studies.
All files must follow this standard layout, and the
information contained in the presentation report must be
consistent with the content of the technical reports.
3) Technical reports can be drafted in French or
English. However, the choice of language must be
uniform for all of the technical reports produced.
For technical reports written in English, a French
English glossary of the technical terms is required.
If a budget impact study has been conducted, it must
be introduced in a separate technical report.
The technical reports must allow the SEESP to
appreciate the compliance of the working methods
with the HAS guidelines, and they must describe the
obtained results clearly and without ambiguity.
The opinion delivered by the HAS is founded on
a critical analysis of the study’s conformity with
the guidelines, hence the need for these reports to be
extremely thorough and the chosen methodology
well argued.
The general objectives of the technical reports are
outlined in the HAS procedural guideline as follows:
a. Present the context and the objectives of the
analysis.
b. Present the retained methodological choices
and data sources.
c. Explain and justify any dispensation or
failure to meet the HAS guidelines and
recommendations.
d. Present the results of the main analysis and
those of the auxiliary sensitivity analysis.
e. Discuss the results with regard to the uncer-
tainty levels and the results of other documen-
ted evaluations.
f. Present any complementary analysis con-
ducted by the manufacturer.
Health economic assessment of pharmaceuticals in France
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4) Computer files
The computer files containing the economic model
and the budget impact study, when appropriate,
must be provided to the CEESP.
The committee favours the following software: Excel,
Treeage, Treeplan, and poptools (Excel environment).
The use of any other software must be justified,
based on technical arguments. Furthermore, the
necessary documentation for understanding of the
models under a different software environment must
be presented.
The files must not be presented in read-only mode.
The parameters must be clearly identified, and the
values attached to them must be open for modi-
fication in order to allow unrestricted use of the
model to appreciate the model dynamic and levels of
uncertainty.
5) Appendix
The following items must be attached to the file’s
appendix:
a. A copy of the file deposited at the CT or the
CNEDIMTS.
b. A copy of the file deposited at the CEPS.
c. A copy of the bibliographic references of the
file and, in particular, the scientific publica-
tions and the evaluation reports from other
agencies.
Timeline and steps of the procedure
Early advice meetings
At the early stages of the health economic evaluation, and
before conducting any studies on the cost-effectiveness of
their product, the drug manufacturer has the option of
consulting with the SEESP to discuss their methodological
choices.
This procedure is referred to as ‘Early Meetings’, and it
aims to ascertain that the health economic assessment
work conducted by the manufacturer and submitted to
the CEESP follows the methodological guidelines of the
latter.
Furthermore, the early meetings allow the drug
manufacturer to grasp the specific features of the disease,
in terms of funding and coverage, as well as to conduct an
overview of the available data and explore the relevant
methods to complete it (14).
Early meetings can be conducted during, or before, the
late-stage clinical trials. At this point, they aim to help the
manufacturer design their trials in a way that allows them
to collect the relevant data for the upcoming economic
evaluation.
Likewise, the drug manufacturer is free to approach the
SEESP at a later stage, when the clinical trials have been
conducted successfully, in order to discuss the most relevant
methodology for their health economic assessment.
This procedure is optional, nonbinding, confidential,
and free of charge.
Early advice application
When applying for this procedure, the drug manufacturer
must file a dossier containing:
1) An application form.
2) A general description of the assessed product and
the addressed pathology.
3) A detailed description of the economic evaluation
protocol.
4) A list of questions related to methodological issues,
addressed to the SEESP, as well as the company
position on these questions.
5) The publications related to the evaluation model
(only in case the evaluation protocol rests on a pre-
existing model).
The HAS examines the dossier and checks whether
there are sufficient grounds to organise an early meeting.
If so, then the date is determined according to the
available time slot.
Early advice meeting
During the meeting, the drug manufacturer can be
assisted by the authors of the study if they belong to a
third-party organisation. However, the HAS guidelines
state that the number of participants on behalf of the
manufacturer must be ‘reasonable’.
The HAS personnel and representatives, as well as
their appointed third-party experts, are all bound by a
confidentiality clause and have no authority to release
any of the information brought to their attention during
the deliberations. However, the HAS will decline any
proposition to sign a supplemental confidentiality agree-
ment submitted by the manufacturer.
The experts appointed by the HAS for the purpose of
these meetings cannot be hired by the manufacturer for
the conduct of the study.
Early advice meeting minutes
After the meeting, the manufacturer is required to draft a
meeting report following a simple structure that is outlined
in the HAS guidelines. The report must be submitted
to the HAS within 30 days of the end of the meetings.
The report will be altered by the HAS representatives if
necessary, and a copy will be returned to the manufacturer.
The content of this report will not be published by the
HAS (Fig. 4).
Standard advice
The file submission by the manufacturer marks the
official launch of the health economic appraisal proce-
dure. The instruction time will be calculated starting from
the day of receipt of the applicant’s file by the CEPS.
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During the allocated period of 180 days, the file will go
through the following steps (Fig. 5) (15).
Preliminary analysis
Immediately after receipt of the file by the HAS, the
content will be checked for compliance with the admin-
istrative rules and guidance. In the event of any required
documentation or information being missing, the instruc-
tion will be suspended until the completion of the
file, and the processing times and deadlines will vary
accordingly.
After validation by the administrative services, the
file will be checked for admissibility of the study protocol.
At this stage, the details of the protocol are not examined
Fig. 4. Steps of the early advice meeting.
Fig. 5. Economic appraisal process. Adapted from HAS, Economic appraisal process (8). *Administrative compliance and scientific/
methodological compliance. Key actors: 23 project managers from the Health Economics and Public Health Department
(SEESP)economics sub-committee rapporteurpossibility to submit questions to external clinical and/or methodological experts.
**Key actors: the CEESP members: economic, clinical public health, and social science experts (monthly meeting).
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yet, but are overviewed to make sure the content of the
file is relevant to determining the cost-effectiveness of
the product. Otherwise, the file will be immediately
returned to the applicant along with a statement of
rejection.
Methodological analysis
This phase is conducted by the project managers of
the SEESP. It is a standardised procedure conducted
in accordance with the guiding principles stated in two
reference documents issued by the HAS and the College of
Health Economists (11, 16).
The critical analysis of the methodology is thoroughly
discussed by the project managers of the SEESP with
their counterparts of the SEM and SED. It is then
drafted in detail. For each part of the study, the draft
shows a neutral presentation of the methodology adopted
by the authors of the study, followed by a thorough
critical analysis. The draft is appended to the opinion
form and will serve as a basis for further discussion by the
economics subcommittee and the CEESP.
The dossier is then discussed during a meeting with the
members of the economics sub-committee of the CEESP,
and both parties agree on a list of questions concerning
the methodology to be addressed to the manufacturer.
Questions to the manufacturer
After meeting with the members of the economics
subcommittee, the project managers of the SEESP direct
their questions to the manufacturer. The manufacturer
has the option to either return written answers by the
deadline, which is set to 8 days before the next meeting
of the sub-commission, or apply to be present at the next
meeting of the sub-commission within 8 days from receipt
of the questions.
First draft
At their next meeting, the economics subcommittee
examines the written or verbal answers of the manufac-
turer. A first opinion is then drafted in accordance with
the initial methodology analysis and the manufacturer’s
answers. It is discussed and approved by the CEESP at
their next meeting, and then forwarded to the manufac-
turer within 5 days.
Adversarial phase
Within 8 days of their receipt of the opinion draft, the
manufacturer can either address a list of written obser-
vations or request an audience with the president of the
CEESP. The audience is scheduled for the next meeting of
the CEESP, or the one after in case of a short notice.
Final draft and opinion
The opinion draft can be altered after the audience with
the manufacturer. In any event, a final opinion is adopted
by the CEESP at the end of the hearing stage. It is then
forwarded to the CEPS and to the manufacturer, and it is
published on the HAS website after price negotiation.
Discussion
French specificities
There are three French specificities:
. The parallel process for the TC and the CEESP.
. Health economics is used for price setting and not
reimbursement.
. The perspective of health economics evaluation
is neither the health insurance nor the social
perspective.
Health economics encounters a big
misunderstanding
Most reports supported that health economics should
be introduced as a rationing tool to address budget
constraints. In fact, health economics aims to support
decision making and not to ration access. However, this
confusion is not specific to France.
Health economics has become an irrevocable part
of the HTA process
In light of these changes, it is evident that cost-
effectiveness studies will now be part of market access
requirements for all drugs satisfying the selection criteria
for health economic assessment (17). From 3 October
2013 to December 2014, 68 dossiers were examined by
the CEESP, 26 of them were judged eligible (25 drugs
and 1 medical device), and 11 dossiers were being
examined at that date (18).
The application decree targets the budget impact,
as well as the incremental benefit, as being the drivers
for eligibility for health economics assessment of drugs.
It has become apparent that the legislator’s question
was: ‘What should the cost be for a given added benefit?’
It is expected health economics will help addressing that
question; however, the lack of clear reference cases and the
lack of an Incremental Cost-Effectiveness Ratio (ICER)
threshold will make it difficult to provide an answer.
The CEESP is expected to inform on the compliance of
health economic evaluations with the HAS guidelines,
but not to inform on whether the intervention is cost-
effective or not. The parliament debate and the new
law impact study refer to quality of life as the effectiveness
outcome for health economic assessment. This leaves little
doubt on the expected preeminent role of quality-related
life-years (QALYs), although this term was not pro-
nounced or written in publicly available documents dur-
ing the parliament debates. This is consistent with the
CEESP-HAS guidelines.
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Major sources of inefficiencies should be addressed
The legislator in charge of the law setting and the executive
administration in charge of issuing the application decree
may have underestimated the source of inefficiencies
associated with this new law.
. The number of cases for which a health economic
assessment would be performed but not used for
decision making was not taken into consideration in
the drugs selection criteria for health economic
assessment. Indeed, companies claim ASMR I, II,
or III in a large proportion of cases, while only a few
get such an outcome. For example, in 2013, for a
first listing drug assessment, 1 ASMR I, 0 ASMR II,
and 8 ASMR III were granted for 10 ASMR IV and
148 ASMR V (19, 20). Products that get ASMR IV
or V are not expected to have an impact on the
pharmaceutical budget according to French regula-
tion. This is one of the important French pharma-
ceutical pricing rules (21). As such, if a product has
claimed an ASMR I, II, or III but is eventually
granted an ASMR IV or V by the CT, the health
economic assessment that was already completed
and submitted in theory should not be used for
pricing decision making (17). As most of the
submitted dossiers benefit from a consultation with
the SEESP, the current process leads to a substantial
waste of resources to manage and review those
applications that will ultimately receive an opinion
that is not supposed to be used. However, the CEPS
claims to use it, but it is unclear how this impacts
the price and rebate.
. There is a duplication of work within the same
organisation, HAS, as both committees (the CEESP
and the CT) assess the public health impact for
any submitted intervention and, to a lesser extent,
the effectiveness or even the efficacy. This may be
considered another source of inefficiency.
. As both committees operate independently and
concomitantly, it is urgent that a clear process is
established to clarify the resolution of divergent
opinions. While the CT only focusses on clinical
evidence, the CEESP is expected to have a broader
perspective but be driven initially by the same
clinical evidence. Divergent assessment of the same
evidence is possible or even likely, and it should
be prevented for the consistency of overall HAS
opinions. The chairman of HAS expressed publicly
that such divergences will be resolved within the
High College of HAS; however, no information
on the process is available. It may not be the most
appropriate place to address those divergences as
the chairman of the College is also the chairman
of the CEESP. Not only does that situation raise
an issue about a transparent process of resolution
of divergences, but such effort appears as another
source of inefficiency.
There are multiple sources of confusion
This decree creates confusion and conflicting information
with respect to the current regulation and practices.
It is can be observed that many of the HAS recommen-
dations on the eligibility criteria for the health economic
assessment of drugs were not implemented in the decree
(20, 22).
. This new situation appears to conflict with regula-
tion in force regarding the external reference pricing
(ERP) (versus the United Kingdom, Germany,
Spain, and Italy) for products with ASMR I, II, or
III. Although criticised, ERP is still in force (23).
How will the health economic evaluation interfere
if the prices of such products are set by ERP, based
on the ‘accord cadre of 2012’ (24)?
. No information specifying how the CEESP opinion
will impact pricing negotiation is available, espe-
cially as it may not impact the price for the first
5 years, which is set by ERP (24).
. Recently, the chairman of the CEPS expressed that
the CEESP cost-effectiveness opinion is not used
for setting listed prices but rather to set the rebates
and ensure that the net price is cost-effective. This
is inconsistent with the lack of ICER threshold
considered, which is an important feature of the
French paradigm. Moreover, without any threshold,
it becomes extremely difficult to have a transparent
discussion on the price.
. At the same time, the chair of the CEPS com-
municated that rebates above 20% would not be
accepted any longer and should lead to price
decreases rather than high rebates. If a threshold is
available and the listed price is set by ERP and the
net price by the ICER threshold, a maximum of
a 20% price rebate should be sufficient to render
all products cost-effective. Based on the UK’s
experience, however, this is quite unlikely, as rebates
of 50% and more are quite frequent.
Interactions of CEESP and CEPS
In order to secure a proper interpretation of the cost-
effectiveness opinion by the CEPS, the head of the
SEESP is often invited to attend the CEPS meetings to
provide additional explanations and clarification, result-
ing in confusion regarding roles and responsibilities.
The pricing and reimbursement decision making should
be based on the three usual phases: the assessment,
the appraisal, and the pricing and reimbursement deci-
sion. The assessment gathers exhaustive information
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and analyses it in an objective way through a predefined
framework. In the appraisal phase, this evidence is con-
sidered and weighted according to a value judgement.
Within the CEESP, this deliberative process is managed
within the same committee as the assessment, unlike the
UK HTA, National Institute for Health and Care
Excellence (NICE). The transparency and reproducibility
of this process are only possible if driven by a clear
decision framework, which does not exist within the
CEESP. Currently, the available decision framework only
allows one to address the conformity to the HAS health
economics’ guidelines. The lack of standardized appraisal
process coupled with the limited insight of the CEPS
in health economics explain the need for the CEPS to
directly interact with the SEESP head in the decision
meetings, which may create confusion and biased deci-
sions. Some of the CEPS members should be qualified to
interpret the health economic data properly. The review
of the modelling outcome and sensitivity analysis on drug
price, performed by the CEESP, should stand alone in a
public report to ensure equitable handling of all applicant
dossiers. Clear appraisal guidelines should be developed.
Conditional pricing may become the rule
Although it is not stated in any document, the CEPS
likely may be tempted to use real-life studies as a
requirement for price re-evaluation. It is recommended
by the CEESP to confirm in real life the ICER that is
estimated from modelling. This would establish ‘Cover-
age with Evidence Development’ with or without escrow
agreement as a principal in France. France is already
quasi-systematically requesting observational drug utili-
sation studies, often with no specific objectives. In that
case, documenting ICER in real life may become the
real unreachable challenge for the pharmaceutical in-
dustry, although there is a trend that such studies are less
requested and/or targeted.
Perspective
Preamble
This section stands on the personal opinion of the authors
based on their historical experience and insight regard-
ing the French administration processes, their personal
interpretation of decisions, and the decision makers’
public presentations and comments. It should be consid-
ered speculative, but it has been discussed with experts in
the field, including former decision makers who consid-
ered it relevant and very plausible. It was neither presented
nor discussed with any decision maker on duty.
The introduction of the economic evaluation of health
products in France happens within a conflictual environ-
ment and important resistance from both the industry
and the CEPS members. There have been incisive queries
from Parliament and the French Court of Auditors on the
lack of use of health economic evidence in price setting
in France (3). It was suggested that this was leading
to unjustified high prices of pharmaceuticals. Due to
substantial resistance, the current regulation is a compro-
mise that is intended to evolve. Therefore, the current
process is likely a transition step toward a wider use of
health economic evidence.
Organisation of the CEESP favours the economic
approach over public health
Current organization of the CEESP reflects a strong
empowerment of health economists in the committee.
The CEESP seems much more focussed on economic
evaluation than public health, although both are inter-
related. Indeed, the CEESP initially created a subcommit-
tee on economics in which only economists participated.
Then, as there was no subcommittee for the public health
mandate of the CEESP, a subcommittee focussing on
human and social sciences was created to balance the
roles of the CEESP, thus leaving a narrow place for public
health. One vice president used to be a public health
specialist, but there are no longer public health specialists
in the role of vice president. Finally, the internal assessors
are mostly econometricians and very few public health
specialists. The public health specialists hired in that
position tend to move over time to other positions within
or outside the HAS. This imbalance is also obvious when
reading the CEESP guidelines and opinions. The CEESP
developed a clear decision framework for the economic
evaluation, but none is available for the public health
assessment. This statement is also in line with the content
of the CEESP opinions published to date, in which the
technology reviews focussed mainly on economics evidence.
There is a growing trend restricting the public health
role of the CEESP to the economics perspective, thus
leaving the core scope of public health unaddressed. This
seems to be more related to the high expectation and
scrutiny of policy decision makers, the Parliament, and
the ministry of health on the health economics evidence
expected to resolve the budgetary constraint than to
a conscious decision to neglect the public health aspect
of decisions. It is likely that this situation will not be
sustainable in the long run. Decisions should first be
driven by the public health interest of the society. Public
health could not be restricted to the CT clinical perspective
and the CEESP economics perspective. Decisions should
integrate the national public health priorities and the
public health impact assessed through a robust and
transparent decision analysis framework. However, it
remains unlikely to be addressed in the short term.
Extension of health economic evaluation
. In the near future, the question of economic eval-
uation of products granted an ASMR IV is likely,
as such drugs may have a considerable economic
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impact, despite bringing a modest clinical benefit
from the CT perspective. The same question applies
to products with ASMR V, but the French HTA
and pricing process are already changing rather
quickly and ASMR Vgranted products may not be
a priority. Assessing the ASMR V drugs will also
imply important increased resources for SEESP, as
most products are granted ASMRV. Moreover, many
of the drugs with ASMR IV benefit from an early
consultation with the SEESP and file a dossier that is
reviewed. The extension of health economic assess-
ment to ASMR IV products may be an important
point of discussion in Parliament during the last
quarter of 2015 for the Social Security financing bill
of 2016. In its report published in 2014, the General
Inspectorate of Social Affairs (Inspection Ge´ne´rale
des Affaires Sociales, or IGAS) has also pointed out
the need to broaden the health economic assessment
to a larger number of products, regardless of the
nature of the health intervention concerned, notably
for clinical practice recommendations or the defini-
tion of health strategies (25).
Merging of the CEESP and the CT
The modelling exercise aims at complementing the
clinical evidence as well as providing additional informa-
tion considered as unavoidable for appropriate decision
making (26). There is a duplication of work within the
same organisation, HAS (i.e., in the CEESP and the CT),
that is unique among all HTA organisations in the world.
This duplication may be considered inefficient in future
and lead to merging both committees and setting a new
harmonised decision framework. Nevertheless, the ad-
ministration is quite resistant to changes. The principle
driving the CT assessment has not changed since its
first implementation by the first chairman of the CT.
The various attempts to change those rules came to
failure (4) even when supported by both the chairman
of the HAS and the College (17). The administration and
those overseeing health insurance remain very apprehen-
sive as they fear that any change may later affect price,
reimbursement, and budgets. However, under increasing
budget constraints, accepting duplicate work will soon
become difficult, especially when this duplication occurs
within the same agency.
It should be noted that medical practice in France
is historically primarily driven by clinician research and
their experience, rather than by public health research.
The role of public health research in France is consider-
ably lower than in Anglo-Saxon countries. In order to
be qualified to specialise in public health in France,
one must follow the medical doctor education first and
then specialise in public health (this is by far the most
prominent path). For a long time, this speciality has been
a default choice for physicians. Consequently, most
decision making and experts’ positions in a broad range
of policy-making bodies in France are held by clinicians
who tend to favour clinical expertise in decision making
for population benefit analysis. A substantial number of
Parliament members are also healthcare professionals
with clinical experience. Thus, the clinical practice lobby
remains important in France and may weigh heavily
to maintain a split between the clinical evaluation by the
CT and the economic one within the CEESP. In that
case, the influence of the CT will decrease, and the ASMR
and SMR will become two well-established scores among
others generated by the CEESP. The CEPS will be
responsible for aggregating the information from both
sources in a deliberative process in which ICER will
become increasingly important information. In all cases,
a change in the balance of power is unavoidable.
It would therefore be expected that the CT holds a
qualitative and clinically oriented assessment of efficacy
and effectiveness. Simultaneously, the CEESP would hold
a comprehensive and quantitative assessment, including
relative effectiveness, cost-effectiveness, budget impact,
and public health impact, and may become the leading
organisation for health intervention assessment for public
health decision makers as well as for price and reimbur-
sement setting. However, to ensure that this happens, the
CEESP must establish and validate a scoring system that
should go beyond ICER to be recognized in France;
nonetheless, ICER clearly will become an important and
even predominant score among others.
That situation will establish clear-cut responsibilities
between consultative technical commissions (e.g., CEESP
and CT) that provide a technical opinion and a decision
body (i.e., CEPS) that will integrate all information in a
deliberative appraisal process to make a policy decision.
This will not address the lack of public health focus of
both committees but will rather enhance the dual focus
on clinical aspects on one side and economic aspects on
the other side.
Establishment of a French threshold
The lack of threshold stands as a real issue in using
ICER to inform decision making. This encourages inter-
minable discussion regarding price setting and the lack
of a transparency process. Manufacturers often complain
about the lack of predictability of price setting in France.
Even if a health economic evaluation provided by a
manufacturer is rated as fully compliant with the HAS
guidelines, this does not indicate how much the payer
should compensate for that intervention, although this
was the question raised and supposed to be addressed by
the legislator through this law.
The lack of expertise to appreciate such informa-
tion could prove critical for the CEPS. The confusion
of mission and responsibility between both committees is
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a real problem and leads to the question of how much the
CEESP/SEESP impacts decisions through potential jud-
gement conveyed to the CEPS. The CEESP is expected
to give its opinion to the CEPS (which acts as the
decision maker), not to enter into a dialogue. In future,
experts in the field may be appointed in the CEPS or as
experts to advise the CEPS. It would make sense that
current members of the CEESP may become members
of the CEPS to help optimise the use of the CEESP’s
opinion.
There is no doubt about the high integrity of CEPS
and SEESP/CEESP members. The issue is compliance
with the process so that HTA reports submitted to the
payers are transparent enough to stand alone. This does
not prevent payers from raising written questions or
clarifications to the HTA body.
It is, however, interesting to notice that if the price
of products granted ASMR I, II, or III is set by ERP,
the discount seems to be set based on the cost-effectiveness.
If no threshold is available, the CEESP informs the
committee about a range of a pharmaceutical’s prices
and their related ICER. It is thought that an intuitive
moving threshold does exist and is used by the CEPS.
This threshold depends on various criteria such as the
severity of the condition, the prevalence, the budget
impact, the clinical benefit, the availability of alterna-
tives, and the impact on healthcare organisations. As
the economic evaluation impacts the rebates, and the
rebates in France are composite  even if widely driven by
a complex pricevolume agreement  and confidential,
it is impossible for an outside observer to apprehend this
moving threshold. The Chairman of the CEPS acknowl-
edges that his decision of limiting the difference between
net and listed price to 20% may not be applicable when
setting the rebate with the support of health economic
assessment.
The French threshold exists intuitively but not as a
hard value. Furthermore, it is not a key driver, as in the
UK, but is instead modulated by a number of attributes,
which not all are fully explicit. The French threshold
ranges from t50,000 per QALY to as high as t300,000
per QALY for some rare conditions or oncology drugs.
There is a clear perception that the French informal
moving threshold may be outstandingly high compared
to that of other countries. For example, in the UK, the
threshold is considered to be between £20,000 and
£30,000 per QALY. In a recent report, Claxton and
colleagues estimated the actual cost per QALY for the
UK National Health Service (NHS) at around £13,000
(27). However, more time and decisions are needed to
have a clear understanding of the actual French thresh-
old. In France, the decision mainly remains a delibera-
tive decision where the chairman of the CEPS retains
a major role through the head-to-head negotiation
with the general manager representing the manufacturer.
In a recent report from IGAS, a reimbursement decision
based on ICER was considered utopian (25). However,
it was acknowledged that this is already used for
infrastructure building where the life-year is valued at
about t50,000. Additionally, the HAS just finalized a
review on ICER threshold giving support to the belief
that this question is becoming a hot topic (28). Within
this report, they referred to the report from the ‘Com-
missariat general a la strate´gie et a` la prospective’, which
valued a life-year at about t100,000. This review may
inform the Minister of Health and the Parliament on
the 2016 Social Security financial law to be voted on in
late 2015. This would represent a major shift in HTA
in France.
Budget impact analysis to become mandatory
The recent case of sofosbuvir, a new antiviral therapy for
hepatitis C virus (HCV) infection, is very illustrative of
the limitations of ICER information to address budget
constraints. ICER will not address an item’s affordability,
unless there are appropriate tools to adjust the threshold
to horizon-scanning spending-forecast information, or
interventions that are unlikely to be fully identified at the
time of decision making are displaced.
Following sofosbuvir’s market entry, the sustainability
of National Health Insurance in many EU countries
was threatened because of the drug’s potential budget
impact. The French administration took a leading role
on the executive and legislative sides in the EU. The
current price regulation was unable to contain the budget
impact of sofosbuvir, and Parliament decided on a
yearly budget cap for the HCV anti-infective drugs.
This illustrates, on one hand, the inappropriateness of
current pricing regulation to control budgets and, on the
other hand, the increasing importance of budget impact
analysis. It is also interesting to notice that the French
silo view prevailed, as the budget cap is drug specific and
excludes all other interventions and other costs. Many
new innovative therapies that may dramatically change
some chronic disease management are expected during
the coming decade. If budget impact becomes a criti-
cal tool to inform budget cap decision making, it will
likely become mandatory together with cost-effectiveness
analysis.
Multi-criteria decision analysis
Although the implementation of a threshold is likely
in France, more solutions to enhance the transparency
of the appraisal decision framework are under review.
Multi-criteria decision analysis (MCDA) is currently under
close investigation at the HAS as an alternative to feed the
deliberative process. HTA decision making is complex,
and multiple facets participate in the evaluation of an
intervention. Increasingly, new interventions are compet-
ing within the same population with heterogeneous
profiles, thus making the decision complex. In the absence
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of a structured decision process, this leads to inconsisten-
cies among decisions and oversimplification of the ques-
tions. MCDA aims to identify and explicate all criteria
used in decision making and to provide the relative weight
of all criteria in comparison with one another. Then, it
should allow defining an aggregated score and a threshold
for accepting a new intervention. It is unlikely that such a
process will land in France because of methodological
issues that remain to be addressed. Nonetheless, being
able to set a list of relevant criteria for decision making
and grouping them in three classes according to their
importance in decision making will already be mazjor
steps forward. This will enhance transparency for the
appraisal.
CEESP will broadly inform CEPS
Today, the CT is not required to take drug price into
consideration, and the CEESP is, even though it should
not be involved in price negotiation. However, when
submitting the HTA dossier to the CT, it is expected that
the company submits it at the same time as the CEPS
pricing dossier. This tends to integrate the price of drugs
in decision making, especially for the CT, which is not
expected to use this information. It was considered that
this may create unwanted interaction between commit-
tees that are not expected to exchange prices. Historically,
pricing dossiers were presented and discussed with the
CEPS after the final conclusion of the CT. In the future,
in order to make a distinction between the two steps, this
may again be separated and an application dossier filled
out sequentially.
The CEESP has a good idea of the manufacturer’s
expected price as it is critical information in the health
economic assessment. If the pricing dossier is submitted
sequentially to CEPS, it will grant the manufacturer an
opportunity to integrate the HTA decision in the pricing
dossier. It is logical to use the outcome of HTA opinion
to develop the pricing dossier or define the expected price.
This is also a change that is likely to be considered by
Parliament in the near future.
For pricing benchmarks, the CEPS uses the daily
price, episode-of-care price, or yearly price of the reference
product. These discussions occur within the CEPS with-
out involvement of the HTA bodies, and as such, they
remain independent of all public health, epidemiologic, or
clinical expert considerations. They are primarily driven by
an accounting perspective. As most drugs are expected to
be granted an ASMR IVor V in France, they are expected
to be priced at a level that implies no budget impact on the
therapeutic class. However, the way a drug may be used on
a specific target population (at a specific dosage or
duration) compared to currently available drugs on the
market may more or less have a legitimate impact
on the therapeutic class budget. The CEPS mission and
expertise are not primarily in epidemiology and public
health and forecasting models, despite the fact that
eminent experts are members of the CEPS. In future,
these studies, performed by the manufacturer and deeply
scrutinised and discussed within the CEPS, may be
reviewed and amended by the CEESP, as they are within
its core expertise.
CEESP will review and inform early-entry agreements
Finally, the CEPS systematically develops a number of
confidential contractual agreements associated with the
market access of new drugs called under a contract-called
convention. This may include pricevolume agreements
(the most common in France), coverage with evidence
development, payment for performance, and eventually
risk-sharing agreements and various forms of rebates,
discounts, linkage to benchmark drug price, and so on.
As in the UK, where the HTA NICE assesses the impact
of such agreements for the Department of Health and
the NHS, it may become the CEESP’s mission to review
those agreements in the future, to model the actual
net price under various assumptions, inform the CEPS
decision making. This would seem justifiable as they have
the expertise to execute that mission and ensure a more
accurate budget impact analysis of such market access
agreements.
Conclusion
Although requested by various high-level bodies in
France, the Manufacturers’ Union as well as the CEPS
delayed the introduction of health economic assessment
in new technology price setting. The situation did change
gradually, but over a period of 8 years, it has been a
dramatic transformation. The legislator and executive
administration may have not fully anticipated the areas
of inefficiencies, conflict, and confusion associated
with this law. However, it may have also resulted from
political compromises. The issued application decree still
leaves some areas of uncertainty that must be addressed
surrounding the introduction of health economics in
market access of drugs in France. The decree creates
confusion and conflicting information with respect to
existing pricing regulation and practice, especially for the
ERP. The experience will set the new practice and rules.
However, active discussions are still ongoing in France
on the development of the use of health economics to
inform public health decision making and ensure the
optimal use of available resources to maximise the
population’s health. At present, the major issue relates to
the lack of an ICER threshold, which seems circumvented
by the CEPS and the CEESP. The current situation should
be considered a transitional period, and major steps are
expected to occur in the near future. The 4-year cycle
may continue to be the appropriate tempo for future
reforms: 2016 (as did 2012 and 2008) will fall 1 year before
presidential and Parliament elections, which is appropriate
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timing for impactful reforms. The application decree
will arrive after the election, which will leave a peaceful
window before actual implementation, as for the 2012
law (2). This is an opportunity to show a strong will to
reform with no risk of overreaction. Empowerment of the
CEESP (merged or not with the CT) is expected, and it
may become the unique or leading committee address-
ing the HTA of pharmaceuticals in France. However, it is
likely that the robust and well-established methodology
developed by the CT to assess comparative efficacy or
effectiveness will remain in force. The reinforcement of
a standardized appreciation of public health impact of
new technologies may remain neglected as successive
French administrations have shown historically and cur-
rently very little appetite for this field. The develop-
ment of a transparent appraisal decision framework will
likely emerge.
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